Lexicon Pharmaceuticals (LXRX) Set to Announce Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) is scheduled to release its earnings data after the market closes on Thursday, August 1st. Analysts expect Lexicon Pharmaceuticals to post earnings of ($0.18) per share for the quarter.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Lexicon Pharmaceuticals had a negative return on equity of 108.54% and a negative net margin of 8,311.12%. The firm had revenue of $1.13 million for the quarter, compared to analyst estimates of $1.17 million. On average, analysts expect Lexicon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lexicon Pharmaceuticals Stock Performance

Shares of NASDAQ:LXRX traded up $0.07 on Friday, hitting $2.40. The company had a trading volume of 599,629 shares, compared to its average volume of 3,657,328. Lexicon Pharmaceuticals has a 1-year low of $0.92 and a 1-year high of $3.73. The stock has a market cap of $590.98 million, a price-to-earnings ratio of -2.89 and a beta of 1.35. The stock has a 50 day moving average price of $1.81 and a 200 day moving average price of $1.98. The company has a current ratio of 15.58, a quick ratio of 15.56 and a debt-to-equity ratio of 0.35.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on LXRX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, May 3rd. StockNews.com raised shares of Lexicon Pharmaceuticals to a “sell” rating in a report on Tuesday, July 9th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Lexicon Pharmaceuticals in a report on Tuesday, July 16th. Leerink Partnrs reissued an “outperform” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, April 30th. Finally, SVB Leerink assumed coverage on shares of Lexicon Pharmaceuticals in a report on Tuesday, April 30th. They issued an “outperform” rating and a $5.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $6.67.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.